A single 120µg dose of Abrysvo generated a strong neutralizing response against both RSV-A and RSV-B in immunocompromised adults. Positive topline data were announced from a phase 3 study ...

Substudy B of the MONeT trial was conducted to assess the safety and immunogenicity of two doses of ABRYSVO, administered one month apart, in four groups of immunocompromised adults: those with ...

Abrysvo was well-tolerated during the trial, showing a safety profile consistent with findings from other studies of the vaccine. Additionally, the FDA approved Pfizer's supplemental Biologics ...

Pfizer announced encouraging top-line results from substudy B of its pivotal Phase 3 MONeT trial, demonstrating that the respiratory syncytial virus (RSV) vaccine Abrysvo is both well-tolerated ...

In the study, a single dose of ABRYSVO generated a strong neutralizing response against both subtypes of RSV, RSV-A and RSV-B, across all cohorts and age groups. Additionally, ABRYSVO was well ...

Pfizer on Monday said that top-line data from a late-stage study regarding its vaccine for respiratory syncytial virus, or RSV, showed that the treatment generated strong neutralizing responses ...

Last week, the 2024 Steve Stevens Masters Tennis Championships took place, bringing together the country's top players over ...

Aug 12 (Reuters) - Pfizer (PFE.N), opens new tab said on Monday its respiratory syncytial virus (RSV) vaccine Abrysvo generated a strong immune response in a late-stage study of four groups of ...

Nurse consultant Linda Nazarko explains the new RSV vaccination programme and how nurses can support patients to understand ...

Global Advisory Committee on Vaccine Safety (GACVS) has released its latest findings, covering the safety of COVID-19 ...

First assessment from an RSV vaccine study in immunocompromised adults show ABRYSVO was well-tolerated and generated strong neutralizing responses after a single dose in adults ≥ 18 years of age ...